

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

November 2, 2022

Consolidated Financial Results
for the First Six Months of the Fiscal Year Ending March 31, 2023
(Under Japanese GAAP)

Listed Company: Zeria Pharmaceutical Co., Ltd.

(Stock Exchange: Tokyo Stock Exchange)

Code Number: 4559

(URL: <https://www.zeria.co.jp/>)

Representative: Mitsuhiro Ibe, Representative Director, President & COO

Person in charge of reference: Tomoyuki Nishizawa, Director, Public Relations Division

TEL (03) 3661-1039

Scheduled date to submit the Quarterly Securities Report: November 7, 2022

Scheduled date to commence dividend payments: December 1, 2022

Preparation of supplementary documents to the quarterly financial results: Yes

Holding of quarterly financial results presentation: Yes (for analysts, institutional investors and the press)

(Amounts under a million yen are truncated.)

1. Consolidated Financial Highlights (April 1, 2022 through September 30, 2022)

(1) Consolidated Financial Results (cumulative)

(Percentage figures indicate changes from the same period of the previous year.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%
Six months ended								
September 30, 2022	33,712	17.9	5,894	120.6	5,182	66.3	3,998	89.0
September 30, 2021	28,606	12.1	2,672	67.2	3,116	138.4	2,115	52.4

Note: Comprehensive income: For the six months ended September 30, 2022: 8,069 million yen [267.7%]

For the six months ended September 30, 2021: 2,194 million yen [10.9%]

	Basic earnings per share	Diluted earnings per share
Six months ended	Yen	Yen
September 30, 2022	90.41	–
September 30, 2021	46.65	–

(2) Consolidated Financial Position

	Total assets	Net assets	Equity ratio	Net assets per share
As of	Million yen	Million yen	%	Yen
September 30, 2022	134,407	61,822	45.8	1,395.01
March 31, 2022	124,282	55,092	44.2	1,236.09

Reference: Equity: As of September 30, 2022: 61,581 million yen

As of March 31, 2022: 54,894 million yen

2. Dividends

	Annual dividends				
	First quarter	Second quarter	Third quarter	Year-end	Total
	Yen	Yen	Yen	Yen	Yen
Year ended March 31, 2022	–	17.00	–	18.00	35.00
Year ending March 31, 2023	–	18.00			
Year ending March 31, 2023 (Forecast)			–	18.00	36.00

Note: Revision of the forecast of dividends most recently announced: None

3. Consolidated Financial Forecast for Fiscal Year Ending March 31, 2023 (April 1, 2022 through March 31, 2023)

(Percentage figures indicate changes from the same period of the previous year.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
Full year	66,000	10.9	7,000	10.0	7,000	17.9	5,600	41.4	126.73

Note: Revision of the financial forecast most recently announced: None

* Notes

(1) Changes in significant subsidiaries during the six months ended September 30, 2022 (changes in specified subsidiaries resulting in changes in scope of consolidation): None

Inclusion: – (Company name: –) Exclusion: – (Company name: –)

(2) Application of special accounting for preparing the quarterly consolidated financial statements: Yes

Note: For details, please refer to “2. Quarterly Consolidated Financial Statements and Significant Notes Thereto, (4) Notes to quarterly consolidated financial statements” on page 10 of the Attached Material.

(3) Changes in accounting policies, changes in accounting estimates, and restatement of prior period financial statements after error corrections

1) Changes in accounting policies due to revisions to accounting standards and other regulations: Yes

2) Changes in accounting policies due to other reasons: None

3) Changes in accounting estimates: None

4) Restatement of prior period financial statements after error corrections: None

Note: For details, please refer to “2. Quarterly Consolidated Financial Statements and Significant Notes Thereto, (4) Notes to quarterly consolidated financial statements” on page 10 of the Attached Material.

(4) Number of shares issued (common shares)

1) Number of shares issued as of the end of the term (including treasury shares):

As of September 30, 2022: 53,119,190 shares As of March 31, 2022: 53,119,190 shares

2) Number of shares of treasury shares as of the end of the term:

As of September 30, 2022: 8,974,949 shares As of March 31, 2022: 8,709,322 shares

3) Average number of shares during the period (cumulative from the beginning of the fiscal year):

For the six months ended September 30, 2022: 44,229,546 shares

For the six months ended September 30, 2021: 45,360,392 shares

* Quarterly Financial Results Are Exempt from Quarterly Review Conducted by Certified Public Accountants or an Audit Corporation.

* Cautionary Statement with Respect to Appropriate Use of Financial Forecast and Other Special Matters

The description about the future including the projection in this document is based on information available to the Company at present and certain presumptions which the Company considers reasonable. Consequently, any descriptions herein do not constitute assurances regarding actual results by the Company. The actual results for future terms may differ from the information in this document due to various factors. For the assumptions made in financial forecasts and cautions concerning the use thereof, please refer to “1. Qualitative Information on Quarterly Financial Results, (3) Explanation of consolidated financial forecasts and other forward-looking statements” on page 4 of the Attached Material.

○ **Table of contents of attachments**

1. Qualitative Information on Quarterly Financial Results	2
(1) Explanation of operating results	2
(2) Explanation of financial position	2
(3) Explanation of consolidated financial forecasts and other forward-looking statements	4
2. Quarterly Consolidated Financial Statements and Significant Notes Thereto	5
(1) Quarterly consolidated balance sheet	5
(2) Quarterly consolidated statement of income and quarterly consolidated statement of comprehensive income ...	7
Quarterly consolidated statement of income	7
Quarterly consolidated statement of comprehensive income	8
(3) Quarterly consolidated statement of cash flows	9
(4) Notes to quarterly consolidated financial statements	10
(Notes on premise of a going concern)	10
(Notes on significant changes in the amount of shareholders' equity)	10
(Adoption of special accounting methods for preparation of quarterly consolidated financial statements)	10
(Change in accounting policy)	10
(Segment information, etc.)	11
3. Supplemental Information	12
(1) Sales results	12
(2) Sales of major products and merchandise Consolidated	13
(3) Status of pipeline of new drugs	14

1. Qualitative Information on Quarterly Financial Results

(1) Explanation of operating results

Net sales for the first six months of the fiscal year ending March 31, 2023 were 33,712 million yen (up 17.9% from the same period of the previous fiscal year). As for profits, operating profit was 5,894 million yen (up 120.6% from the same period of the previous fiscal year), ordinary profit was 5,182 million yen (up 66.3% from the same period of the previous fiscal year), and profit attributable to owners of parent was 3,998 million yen (up 89.0% from the same period of the previous fiscal year). The large difference in the year-on-year growth rate between operating profit and ordinary profit is because although the Company recorded foreign exchange gains in the previous fiscal year, a large amount of foreign exchange losses was recorded in the current fiscal year as a result of the rapid appreciation of the Swiss franc.

Following are the results by business segment.

(i) Ethical Pharmaceuticals Business

As for our mainstay product, Asacol, a therapeutic agent for ulcerative colitis, growth in sales of Asacol 1600mg, a high-dose formulation only on sale in overseas markets, contributed to increased sales. Sales of Entocort (domestic sales name: Zentacort), an inflammatory bowel disease (IBD) therapeutic agent, also increased, as sales grew in the overseas market in various regions, including Canada, Northern Europe, and also Italy, where the Company established a local subsidiary in the previous year. In addition, sales of DIFICLIR, a therapeutic agent for Clostridium difficile infections, achieved a significant sales growth as a result of aggressive investment of sales resources in response to its recommendation as a first-line drug in the European guidelines for the treatment of infectious diseases. With regard to Acofide and Ferinject, we are working to build the market, particularly in medical institutions performing endoscopy, and the domains of gastroenterology, and obstetrics and gynecology.

As a result, net sales in the business amounted to 21,505 million yen (up 19.5% from the same period of the previous fiscal year).

(ii) Consumer Healthcare Business

As for the Hepalyse range, although it is still affected by the spread of COVID-19 infection and a sharp decline in demand from inbound tourists, its sales significantly increased owing to the substantial increase in the sales of the pharmaceutical Hepalyse range, as well as the Hepalyse W range for convenience stores. Sales of the Chondroitin range remained strong, due in part to aggressive advertising and promotional investments. On the other hand, sales of the WithOne range of botanical laxative products decreased due to the impact from competing products.

As a result, net sales in the business amounted to 12,131 million yen (up 15.2% from the same period of the previous fiscal year).

(iii) Other

Net sales in this segment amounted to 75 million yen (up 1.1% from the same period of the previous fiscal year), mainly due to insurance agency business and real estate lease revenue.

(2) Explanation of financial position

(i) Assets, liabilities, and net assets

Total assets at the end of the second quarter of the fiscal year ending March 31, 2023 were 134,407 million yen, an increase of 10,125 million yen from the end of the previous fiscal year. Current assets increased 7,099 million yen to 48,763 million yen from the end of the previous fiscal year, and non-current assets increased 3,025 million yen to 85,644 million yen from the end of the previous fiscal year. Major changes in current assets included an increase of 3,589 million yen in cash and deposits, an increase of 2,512 million yen in notes and accounts receivable - trade, and an increase of 1,080 million

yen in inventories such as merchandise and finished goods. The changes in non-current assets were an increase of 548 million yen in property, plant and equipment, an increase of 2,959 million yen in intangible assets, and a decrease of 481 million yen in investments and other assets.

Total liabilities at the end of the quarter under review were 72,585 million yen, an increase of 3,395 million yen from the end of the previous fiscal year. Current liabilities increased 3,736 million yen to 47,929 million yen from the end of the previous fiscal year, and non-current liabilities decreased 340 million yen to 24,656 million yen from the end of the previous fiscal year. Main changes in current liabilities were an increase of 2,727 million yen in short-term borrowings and an increase of 835 million yen in income taxes payable. Main changes in non-current liabilities were a decrease of 905 million yen in long-term borrowings, an increase of 319 million yen in provision for loss on cancellation of contracts, and an increase of 264 million yen in other non-current liabilities including an increase in deferred tax liabilities.

Net assets at the end of the quarter under review were 61,822 million yen, an increase of 6,729 million yen from the end of the previous fiscal year. This was mainly due to profit attributable to owners of parent of 3,998 million yen, payment of 799 million yen as dividends declared at the end of the previous period, an increase of 536 million yen in treasury shares, and an increase of 4,438 million yen in foreign currency translation adjustment.

As a result, equity ratio at the end of the quarter under review increased by 1.6% from the end of the previous fiscal year to 45.8%.

(ii) Status of cash flows

Cash and cash equivalents (below, “cash”) at the end of the quarter under review increased 3,589 million yen from the beginning of the period to 15,168 million yen. This was mainly due to net cash provided by operating activities of 5,332 million yen, despite net cash used in investing activities of 963 million yen and net cash used in financing activities of 2,119 million yen.

The status of each cash flow and its factors for the first six months of the current fiscal year are as follows.

[Net cash provided by (used in) operating activities]

Net cash provided by operating activities amounted to 5,332 million yen in the first six months of the current fiscal year (up 2,220 million yen from the same period of the previous fiscal year). This was due to factors including profit before income taxes of 4,970 million yen, depreciation of 2,466 million yen, a decrease in provision for bonuses of 514 million yen, an increase in trade receivables of 1,289 million yen, and an increase in inventories of 409 million yen.

[Net cash provided by (used in) investing activities]

Net cash used in investing activities totaled 963 million yen in the first six months of the current fiscal year (up 733 million yen from the same period of the previous fiscal year). This was mainly due to an expenditure of 908 million yen for the purchase of property, plant and equipment.

[Net cash provided by (used in) financing activities]

Net cash used in financing activities totaled 2,119 million yen in the first six months of the current fiscal year (down 1,037 million yen from the same period of the previous fiscal year). This was mainly due to an increase of 1,873 million yen in short-term borrowings, proceeds from long-term borrowings of 500 million yen, repayments of long-term borrowings of 3,028 million yen, purchase of treasury shares of 538 million yen, and dividends paid of 798 million yen.

(3) Explanation of consolidated financial forecasts and other forward-looking statements

The consolidated financial forecast for the fiscal year ending March 31, 2023 remains unchanged from the consolidated financial forecast announced on May 11, 2022. For details, please refer to “Notice Regarding Revisions to Financial Forecasts,” announced on October 31, 2022 (Japanese version only).

2. Quarterly Consolidated Financial Statements and Significant Notes Thereto

(1) Quarterly consolidated balance sheet

(Thousands of yen)

	As of March 31, 2022	As of September 30, 2022
Assets		
Current assets		
Cash and deposits	11,704,282	15,293,974
Notes and accounts receivable - trade	16,206,812	18,719,715
Merchandise and finished goods	6,721,583	7,314,567
Work in process	1,409,684	1,194,974
Raw materials and supplies	3,819,276	4,521,242
Other	1,855,502	1,791,257
Allowance for doubtful accounts	(53,425)	(72,368)
Total current assets	41,663,717	48,763,363
Non-current assets		
Property, plant and equipment		
Buildings, net	6,655,232	6,499,554
Land	12,354,010	12,361,492
Other, net	4,130,101	4,826,460
Total property, plant and equipment	23,139,343	23,687,508
Intangible assets		
Goodwill	5,830,459	5,702,690
Sales right	27,539,473	29,621,682
Other	7,836,095	8,841,092
Total intangible assets	41,206,029	44,165,464
Investments and other assets		
Investment securities	7,005,587	6,681,999
Retirement benefit asset	10,736,005	10,591,887
Other	583,595	564,753
Allowance for doubtful accounts	(51,945)	(47,230)
Total investments and other assets	18,273,242	17,791,409
Total non-current assets	82,618,615	85,644,382
Total assets	124,282,333	134,407,745
Liabilities		
Current liabilities		
Accounts payable - trade	2,049,590	2,425,768
Short-term borrowings	33,842,933	36,570,603
Income taxes payable	458,297	1,293,577
Provision for bonuses	1,530,935	1,068,358
Other	6,311,307	6,570,900
Total current liabilities	44,193,063	47,929,209
Non-current liabilities		
Long-term borrowings	18,385,860	17,480,830
Provision for loss on cancellation of contracts	490,142	809,440
Retirement benefit liability	1,073,819	1,054,164
Asset retirement obligations	55,827	55,929
Other	4,991,146	5,255,834
Total non-current liabilities	24,996,794	24,656,199
Total liabilities	69,189,858	72,585,408

(Thousands of yen)

	As of March 31, 2022	As of September 30, 2022
Net assets		
Shareholders' equity		
Share capital	6,593,398	6,593,398
Capital surplus	11,685,121	11,685,121
Retained earnings	48,860,697	52,059,900
Treasury shares	(17,593,074)	(18,129,863)
Total shareholders' equity	49,546,143	52,208,557
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	(193,416)	(458,313)
Foreign currency translation adjustment	3,215,379	7,653,742
Remeasurements of defined benefit plans	2,326,536	2,177,596
Total accumulated other comprehensive income	5,348,499	9,373,025
Non-controlling interests	197,832	240,754
Total net assets	55,092,474	61,822,336
Total liabilities and net assets	124,282,333	134,407,745

(2) Quarterly consolidated statement of income and quarterly consolidated statement of comprehensive income

Quarterly consolidated statement of income

(Thousands of yen)

	Six months ended September 30, 2021	Six months ended September 30, 2022
Net sales	28,606,173	33,712,480
Cost of sales	8,462,724	9,376,722
Gross profit	20,143,448	24,335,758
Selling, general and administrative expenses	17,470,923	18,441,079
Operating profit	2,672,525	5,894,678
Non-operating income		
Interest income	6,759	26,461
Dividend income	148,091	158,136
Foreign exchange gains	417,551	–
Other	36,809	45,555
Total non-operating income	609,211	230,153
Non-operating expenses		
Interest expenses	148,520	181,259
Foreign exchange losses	–	748,121
Other	16,479	13,205
Total non-operating expenses	165,000	942,586
Ordinary profit	3,116,736	5,182,245
Extraordinary income		
Gain on sale of non-current assets	3,470	260
Gain on sale of investment securities	3,367	19,940
Total extraordinary income	6,837	20,200
Extraordinary losses		
Loss on retirement of non-current assets	3,995	3,350
Provision for loss on cancellation of contracts	–	228,300
Total extraordinary losses	3,995	231,651
Profit before income taxes	3,119,578	4,970,794
Income taxes	998,954	964,014
Profit	2,120,624	4,006,779
Profit attributable to non-controlling interests	4,632	8,199
Profit attributable to owners of parent	2,115,992	3,998,580

Quarterly consolidated statement of comprehensive income

(Thousands of yen)

	Six months ended September 30, 2021	Six months ended September 30, 2022
Profit	2,120,624	4,006,779
Other comprehensive income		
Valuation difference on available-for-sale securities	(320,290)	(264,896)
Foreign currency translation adjustment	720,862	4,476,703
Remeasurements of defined benefit plans, net of tax	(326,784)	(148,940)
Total other comprehensive income	73,787	4,062,866
Comprehensive income	2,194,411	8,069,646
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	2,177,573	8,023,106
Comprehensive income attributable to non-controlling interests	16,838	46,539

(3) Quarterly consolidated statement of cash flows

(Thousands of yen)

	Six months ended September 30, 2021	Six months ended September 30, 2022
Cash flows from operating activities		
Profit before income taxes	3,119,578	4,970,794
Depreciation	2,321,125	2,466,358
Amortization of goodwill	349,467	354,879
Increase (decrease) in provision for bonuses	(305,242)	(514,895)
Increase (decrease) in provision for loss on cancellation of contracts	(28,302)	228,300
Increase (decrease) in retirement benefit liability	110,409	109,324
Interest and dividend income	(154,850)	(184,597)
Interest expenses	148,520	181,259
Decrease (increase) in trade receivables	(1,734,982)	(1,289,682)
Decrease (increase) in inventories	(762,273)	(409,623)
Increase (decrease) in trade payables	143,623	193,809
Decrease (increase) in other current assets	932,126	(164,194)
Increase (decrease) in other current liabilities	(392,234)	215,451
Decrease (increase) in retirement benefit asset	(334,602)	(354,809)
Other, net	(12,593)	(117,947)
Subtotal	3,399,768	5,684,428
Interest and dividends received	154,854	184,616
Interest paid	(140,890)	(180,360)
Income taxes paid	(302,270)	(356,493)
Net cash provided by (used in) operating activities	3,111,463	5,332,190
Cash flows from investing activities		
Purchase of property, plant and equipment	(361,126)	(908,651)
Purchase of intangible assets	(214,326)	(156,032)
Purchase of investment securities	(1,164,456)	(132,488)
Proceeds from sale of investment securities	37,186	215,908
Other, net	5,941	17,787
Net cash provided by (used in) investing activities	(1,696,780)	(963,476)
Cash flows from financing activities		
Net increase (decrease) in short-term borrowings	(7,310,442)	1,873,266
Proceeds from long-term borrowings	10,009,350	500,000
Repayments of long-term borrowings	(1,649,550)	(3,028,710)
Repayments of lease liabilities	(111,162)	(123,158)
Purchase of treasury shares	(1,243,504)	(538,398)
Dividends paid	(773,214)	(798,347)
Dividends paid to non-controlling interests	(3,513)	(3,929)
Net cash provided by (used in) financing activities	(1,082,036)	(2,119,276)
Effect of exchange rate change on cash and cash equivalents	143,687	1,340,254
Net increase (decrease) in cash and cash equivalents	476,334	3,589,691
Cash and cash equivalents at beginning of period	9,668,938	11,579,282
Increase (decrease) in cash and cash equivalents resulting from change in scope of consolidation	129,430	–
Cash and cash equivalents at end of period	10,274,703	15,168,974

(4) Notes to quarterly consolidated financial statements

(Notes on premise of a going concern)

Not applicable.

(Notes on significant changes in the amount of shareholders' equity)

Not applicable.

(Adoption of special accounting methods for preparation of quarterly consolidated financial statements)

Calculation of tax expenses

Tax expenses were calculated by reasonably estimating the effective tax rate after applying tax effect accounting to the profit before income taxes for the fiscal year that includes the second quarter of the current fiscal year and multiplying profit before income taxes by such estimated effective tax rate.

(Change in accounting policy)

Adoption of the Implementation Guidance on Accounting Standard for Fair Value Measurement

The Company adopted the Implementation Guidance on Accounting Standard for Fair Value Measurement (ASBJ Guidance No. 31, June 17, 2021) from the beginning of the first quarter of the current fiscal year. In accordance with the transitional treatment prescribed in paragraph 27-2 of the Implementation Guidance on Accounting Standard for Fair Value Measurement, the new accounting policies prescribed by the Implementation Guidance on Accounting Standard for Fair Value Measurement are to be applied prospectively. There is no impact on the consolidated quarterly financial statements for the first six months of the current fiscal year.

(Segment information, etc.)

[Segment information]

I First six months of the previous fiscal year (from April 1, 2021 to September 30, 2021)

1. Information on net sales and profit or loss by reportable segment

(Thousands of yen)

	Reportable segment			Other (Note 1)	Total	Adjustment (Note 2)	Amount recorded in quarterly consolidated statement of income (Note 3)
	Ethical Pharmaceuticals Business	Consumer Healthcare Business	Total				
Net sales							
Sales to external customers	17,997,949	10,533,349	28,531,299	74,873	28,606,173	–	28,606,173
Intersegment sales and transfers	–	48	48	284,004	284,053	(284,053)	–
Total	17,997,949	10,533,398	28,531,348	358,878	28,890,226	(284,053)	28,606,173
Segment profit	3,081,706	1,976,960	5,058,667	128,480	5,187,147	(2,514,621)	2,672,525

(Notes) 1. “Other” is a business segment not included in the reportable segments and includes the insurance agency business and real estate business.

2. Adjustment of segment profit of (2,514,621) thousand yen is mainly corporate expenses such as general and administrative expenses that are not allocated to reportable segments.
3. Segment profit is adjusted with operating profit in the quarterly consolidated statement of income.

2. Information on impairment losses on non-current assets or goodwill by reportable segment
Not applicable.

II First six months of the current fiscal year (from April 1, 2022 to September 30, 2022)

1. Information on net sales and profit or loss by reportable segment

(Thousands of yen)

	Reportable segment			Other (Note 1)	Total	Adjustment (Note 2)	Amount recorded in quarterly consolidated statement of income (Note 3)
	Ethical Pharmaceuticals Business	Consumer Healthcare Business	Total				
Net sales							
Sales to external customers	21,505,406	12,131,357	33,636,763	75,716	33,712,480	–	33,712,480
Intersegment sales and transfers	2,694	58	2,753	219,681	222,434	(222,434)	–
Total	21,508,101	12,131,416	33,639,517	295,398	33,934,915	(222,434)	33,712,480
Segment profit	5,867,879	2,454,974	8,322,853	116,456	8,439,309	(2,544,631)	5,894,678

(Notes) 1. “Other” is a business segment not included in the reportable segments and includes the insurance agency business and real estate business.

2. Adjustment of segment profit of (2,544,631) thousand yen is mainly corporate expenses such as general and administrative expenses that are not allocated to reportable segments.
3. Segment profit is adjusted with operating profit in the quarterly consolidated statement of income.

2. Information on impairment losses on non-current assets or goodwill by reportable segment
Not applicable.

3. Supplemental Information

(1) Sales results

The table below shows sales results by business segment in the first six months of the current fiscal year.

(Thousands of yen)

Name of segment	First six months of the current fiscal year (from April 1, 2022 to September 30, 2022)	Increase/(decrease) over the same period of the previous fiscal year (%)
Ethical Pharmaceuticals Business	21,505,406	19.5
Consumer Healthcare Business	12,131,357	15.2
Total reportable segment	33,636,763	17.9
Other	75,716	1.1
Total	33,712,480	17.9

(Note) Inter-segment transactions are offset and eliminated.

(2) Sales of major products and merchandise Consolidated

(Thousands of yen)

	First six months of the previous fiscal year (from April 1, 2021 to September 30, 2021)	First six months of the current fiscal year (from April 1, 2022 to September 30, 2022)	Percentage change (%)
1. Ethical Pharmaceuticals Business	17,997,949	21,505,406	19.5
Asacol	8,506,104	9,881,146	16.2
DIFICLIR	2,279,800	3,895,442	70.9
Entocort	2,245,177	2,935,555	30.7
Acofide	1,580,552	1,541,840	(2.4)
Other	3,386,314	3,251,421	(4.0)
2. Consumer Healthcare Business	10,533,349	12,131,357	15.2
Hepalyse range	3,237,728	4,698,724	45.1
Chondroitin range	2,595,823	2,634,015	1.5
WithOne range	647,510	620,943	(4.1)
Other	4,052,288	4,177,673	3.1
3. Other Business	74,873	75,716	1.1
Total	28,606,173	33,712,480	17.9

(3) Status of pipeline of new drugs

I. Domestic

As of November 2, 2022

Stage	Development Code/ Generic Name	Development	Indications	Classification	Origin
Phase III	Z-338/Acotiamide	Zeria	Pediatric functional dyspepsia	Upper gastrointestinal motility modulator	Original
Phase III	ZG-801/Patiromer Sorbitex Calcium	Zeria	Hyperkalemia	Potassium binder	In-licensed
Phase II* (Investigator-Initiated Trial)	Z-338/Acotiamide	Kyushu University	Esophagogastric junction outflow obstruction	Upper gastrointestinal motility modulator	Original

*: Supported by a grant from Japan Agency for Medical Research and Development (AMED)

II. Overseas

Stage	Development Code/ Generic Name	Development	Indications	Classification	Origin
Phase III (Europe)	Z-338/Acotiamide	Zeria	Functional dyspepsia	Upper gastrointestinal motility modulator	Original
NDA approved (Mexico, Honduras)	Z-338/Acotiamide	Faes Farma	Functional dyspepsia	Upper gastrointestinal motility modulator	Original (Out-licensed)
NDA filed (Chile, Colombia, Peru, Ecuador, Dominican Republic, Costa Rica, Guatemala, Panama)	Z-338/Acotiamide	Faes Farma	Functional dyspepsia	Upper gastrointestinal motility modulator	Original (Out-licensed)
NDA filed (Thailand, Indonesia)	Z-338/Acotiamide	Meiji Seika Pharma	Functional dyspepsia	Upper gastrointestinal motility modulator	Original (Out-licensed)